Across TCGA pan-cancer cohorts, ANKRD28 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD28 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ANKRD28 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD28 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

ESCA, UCEC, and ACC are the cancer types where ANKRD28 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.231	0.708	<.001	12	view →
UCEC	DFS	Median	All	0.944	0.613	.006	10	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
COAD	DFS	Median	All	1.000	0.776	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ANKRD28 tumor-vs-normal RNA expression · all ANKRD28 data types